[1
]
From the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital (B.Z.) and the
Divisions of Endocrinology (B.Z.) and Cardiology (D.F.), University of Toronto - all
in Toronto; the Department of Medicine, Division of Nephrology, Würzburg University
Clinic, Würzburg (C.W.), Boehringer Ingelheim Pharma, Biberach (E.B., S.H.), and Boehringer
Ingelheim Pharma, Ingelheim (M.M., H.J.W., U.C.B.) - all in Germany; the Biostatistics
Center, George Washington University, Rockville, MD (J.M.L.); Boehringer Ingelheim
Pharmaceuticals, Ridgefield, CT (T.D.); Boehringer Ingelheim Norway, Asker, Norway
(O.E.J.); and the Section of Endocrinology, Yale University School of Medicine, New
Haven, CT (S.E.I.).